Chemical formula: C₄₀H₅₇N₅O₇ Molecular mass: 719.91 g/mol PubChem compound: 11556711
Carfilzomib is indicated for:
Population group: only adults (18 years old or older)
Carfilzomib in combination with either lenalidomide and dexamethasone or dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Carfilzomib is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
